Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics (NRIX), a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will deliver a corporate update presentation on Monday, January 13, 2025, at 3:00 p.m. PT in San Francisco.
The presentation will be accessible through a live webcast, with a link available in the Investors section of the Nurix website. For those unable to attend live, the webcast recording will remain accessible for 30 days following the event.
Nurix Therapeutics (NRIX), una società biofarmaceutica in fase clinica focalizzata nello sviluppo di farmaci per la modulazione mirata delle proteine per il trattamento del cancro e delle malattie infiammatorie, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il presidente e CEO della società, Arthur T. Sands, M.D., Ph.D., presenterà un aggiornamento aziendale lunedì 13 gennaio 2025, alle 15:00 PT a San Francisco.
La presentazione sarà disponibile attraverso una diretta web, con un link accessibile nella sezione Investitori del sito web di Nurix. Per coloro che non possono partecipare dal vivo, la registrazione della diretta sarà accessibile per 30 giorni dopo l'evento.
Nurix Therapeutics (NRIX), una empresa biofarmacéutica en etapa clínica enfocada en el desarrollo de medicamentos de modulación dirigida de proteínas para el cáncer y enfermedades inflamatorias, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El presidente y CEO de la empresa, Arthur T. Sands, M.D., Ph.D., hará una presentación de actualización corporativa el lunes 13 de enero de 2025, a las 3:00 p.m. PT en San Francisco.
La presentación estará accesible a través de una transmisión en vivo, con un enlace disponible en la sección de Inversores del sitio web de Nurix. Para aquellos que no puedan asistir en vivo, la grabación de la transmisión estará disponible durante 30 días después del evento.
Nurix Therapeutics (NRIX), 암 및 염증 질환을 위한 표적 단백질 조절 약물 개발에 집중하는 임상 단계의 생명공학 회사,가 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 Arthur T. Sands, M.D., Ph.D.는 2025년 1월 13일 월요일 오후 3시 PT 샌프란시스코에서 기업 업데이트 발표를 진행할 예정입니다.
발표는 라이브 웹캐스트를 통해 접근 가능하며, Nurix 웹사이트의 투자자 섹션에서 링크를 확인할 수 있습니다. 실시간 참석이 불가능한 분들을 위해 웹캐스트 기록은 행사 후 30일 동안 접근할 수 있습니다.
Nurix Therapeutics (NRIX), une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments de modulation ciblée des protéines pour le cancer et les maladies inflammatoires, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. Le président et CEO de l’entreprise, Arthur T. Sands, M.D., Ph.D., présentera une mise à jour corporative le lundi 13 janvier 2025, à 15h00 PT à San Francisco.
La présentation sera accessible via une diffusion en direct, avec un lien disponible dans la section Investisseurs du site web de Nurix. Pour ceux qui ne peuvent pas assister en direct, l'enregistrement de la diffusion restera accessible pendant 30 jours suivant l'événement.
Nurix Therapeutics (NRIX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung gezielt wirkender Proteinmodulationsmedikamente gegen Krebs und entzündliche Erkrankungen spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Der Präsident und CEO des Unternehmens, Arthur T. Sands, M.D., Ph.D., wird am Montag, dem 13. Januar 2025, um 15:00 Uhr PT in San Francisco eine Unternehmensaktualisierung präsentieren.
Die Präsentation wird über einen Live-Stream zugänglich sein, wobei ein Link im Investorenbereich der Nurix-Website verfügbar sein wird. Für diejenigen, die nicht live teilnehmen können, bleibt die Aufzeichnung des Streams für 30 Tage nach der Veranstaltung zugänglich.
- None.
- None.
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:00 p.m. PT, in San Francisco.
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types, including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When is Nurix Therapeutics (NRIX) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will the NRIX J.P. Morgan Healthcare Conference webcast be available?
What therapeutic areas does Nurix Therapeutics (NRIX) focus on?
Where can investors access the NRIX J.P. Morgan Healthcare Conference presentation webcast?
